MNG1215
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.631
- ALLOGRAFT_REJECTION+0.561
- INFLAMMATORY_RESPONSE+0.549
- INTERFERON_GAMMA_RESPONSE+0.528
- IL6_JAK_STAT3_SIGNALING+0.502
- PROTEIN_SECRETION+0.426
- ANDROGEN_RESPONSE+0.421
- INTERFERON_ALPHA_RESPONSE+0.413
- TGF_BETA_SIGNALING+0.411
- COMPLEMENT+0.408
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.206
- DNA_REPAIR-0.195
- OXIDATIVE_PHOSPHORYLATION-0.180
- PANCREAS_BETA_CELLS-0.111
- KRAS_SIGNALING_DN-0.062
- HEDGEHOG_SIGNALING-0.058
- NOTCH_SIGNALING-0.006
- SPERMATOGENESIS+0.005
- MYOGENESIS+0.012
- APICAL_JUNCTION+0.024
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013563 | — | cohortMD2 | 0.905 |
| 2 | TCGA-98-7454-01A-11R-2045-07 | — | cohortMD2 | 0.899 |
| 3 | SRR934866 | — | — | 0.891 |
| 4 | SRR934811 | — | — | 0.890 |
| 5 | SRR934741 | — | — | 0.888 |
| 6 | BS_1JDG6JV5 | pilocytic astrocytoma | — | 0.888 |
| 7 | SRR1488836 | GTEX | — | 0.887 |
| 8 | TCGA-AR-A24U-01A-11R-A169-07 | — | C | 0.886 |
| 9 | TCGA-K4-A6FZ-01A-11R-A31N-07 | — | — | 0.885 |
| 10 | CB1F8B9C-7CE7-4181-B746-7FC697ED27F4 | — | — | 0.885 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.631 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.561 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.549 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.528 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.502 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.426 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.421 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.413 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.411 | Inavolisib | — uncovered |
| COMPLEMENT | 0.408 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.408 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.381 | Inavolisib | — uncovered |
| APOPTOSIS | 0.375 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.369 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.324 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.319 | Inavolisib | — uncovered |
| HYPOXIA | 0.318 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.302 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.262 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.251 | Remibrutinib | — uncovered |